What the research says about CBG for neuroprotection, appetite, and glaucoma

Reading the grades. The ladder has six rungs: the six-rung evidence ladder. Not supported is reserved for a question that has been tested and has come back against the claim. An untested question, one with no primary study in our registry, gets No primary evidence / catalogue in progress instead, which marks a gap in coverage and sits off the ladder. CBG's chemistry and receptor activity are stated as fact with a grade; any effect or benefit (protecting nerve cells, raising appetite, lowering eye pressure) is credited to whoever claims it, limits attached, because human evidence for these outcomes barely exists. Thin areas are left open instead of filled. None of it is medical advice.

CBG and neuroprotection: what is known

Start with the brain: very little has been shown, and nothing in humans. Neuroprotection means shielding nerve cells from damage. A handful of preclinical reports, in cell cultures and in animals, describe antioxidant and anti-inflammatory activity by CBG in laboratory models of nerve-cell stress, and proponents cite that work when they call CBG "neuroprotective." The research exists. Still, it is early, it has not been repeated in controlled human studies, and a signal in a dish or a mouse is not a benefit in a person. Attributed and hedged, this sits at Emerging at most; for a human claim it is Catalogue in progress.

CBG Atlas cites no specific neuroprotection study, because none has been verified and added to our registry, and a preprint or a single animal paper would lend the topic an authority it has not earned. The area stays catalogue in progress until a study clears review and earns a graded, provenance-stamped citation.

What stands on solid ground is the chemistry that draws researchers in, and nothing beyond it. In laboratory (in vitro) studies CBG acts as an α₂-adrenoceptor agonist, blocks the 5-HT₁ₐ serotonin receptor and behaves as a CB₁ receptor competitive antagonist (Cascio 2010). It also acts on several TRP ion channels (De Petrocellis 2011). All of these receptor systems occur in the nervous system, which explains why CBG gets studied for neurological questions. Receptor activity in a test tube is a reason to investigate, not evidence of protection. Demonstrated · in vitro for the mechanism; no established neuroprotective benefit in people. CBG is not a treatment for any neurological condition.

CBG and appetite

The appetite story has the same shape, with a sales pitch on top: marketing and preclinical work, and no human effect shown. CBG is sometimes marketed as an appetite-supporting cannabinoid. The reputation rests on preliminary animal research, rodent studies that some sources cite as showing CBG can stimulate feeding. On the evidence that puts it at Emerging, attributed to those third-party and preclinical sources, and not established in humans; no controlled human trial has shown CBG changing appetite in a meaningful way. CBG is not an approved appetite stimulant or a weight-management product, and selling it as one would outrun the evidence.

As with neuroprotection, no specific appetite study appears here, because none has been independently verified and added to our registry, so the rodent-feeding claim is catalogue in progress. The nearest verified fact sits next door to appetite: CBG showed anti-inflammatory activity in an animal model of gut inflammation (Borrelli 2013, a mouse colitis study). That gut-focused animal result often gets loosely linked to appetite, but it is silent on whether CBG stimulates appetite in people. Demonstrated · in a mouse model for the colitis finding; Emerging/Catalogue in progress for any human appetite claim.

CBG, glaucoma and eye pressure: correcting a common myth

Here the story turns, because the glaucoma claim was built on a different molecule. Our registry contains no primary study of CBG and eye pressure in either direction, and we do not recommend CBG for glaucoma. No primary evidence. Nothing supports the claim. The myth, at least, has a traceable origin, and a claim with no support is still different from one that has been disproven.

It goes back to older observations that THC, and smoked cannabis, can briefly lower intraocular pressure (IOP), the pressure inside the eye that matters in glaucoma. That research concerned THC and whole cannabis, and CBG was absent from it. Over time "a cannabinoid may lower eye pressure" was flattened into "cannabinoids lower eye pressure," and CBG, a different non-intoxicating molecule with different targets, was pulled in by association. The claim is a conflation with no finding behind it. No evidence on record shows CBG lowering IOP.

Even THC and cannabis have failed to win mainstream eye-care authorities over as glaucoma treatments. Any drop in pressure is short-lived, would need impractically frequent dosing, and comes with side effects, so proven, sustained treatments are used instead. If that holds for the cannabinoid that does show an IOP signal, there is even less reason to experiment with CBG, which shows none. For brands, the upshot is simple: no eye-health claim for CBG has evidence behind it.

A specific safety note, because eyes and blood pressure are linked. In laboratory studies CBG acts on α₂-adrenoceptors (Cascio 2010), part of the system that regulates blood pressure. Blood pressure affects blood flow to the optic nerve, and a fall in systemic pressure is not automatically good for an eye at risk, which is one more reason against self-treating glaucoma with CBG. If you take cardiovascular or blood-pressure medication, treat CBG with caution and talk to a clinician. Glaucoma is a leading cause of irreversible blindness; it is managed by an eye-care professional, not by an unproven supplement. (Not medical advice.)

Three questions to ask of any CBG claim

All three topics come down to the same short set of questions, and they work on a label as well as a headline:

• Where was it shown? In vitro and animal results are a different thing from human benefit, and "active in a dish" has a way of turning into "works for people" once it leaves the lab. Check which one the claim rests on.
• Who is making it? A benefit that is marketed, reported anecdotally or seen only in preclinical work should arrive with its source and its limits ("not established," "catalogue in progress") attached.
• What is the citation? Where our registry lacks an anchor, as with a specific CBG neuroprotection or appetite study, the right answer is a gap. Where a popular claim rests on nothing in our registry, as with CBG and eye pressure, the right move is to correct the myth without pretending to hold a study that disproves it.

CBG Atlas holds itself to the same three: every evidence tier labelled, every effect claim attributed and graded, and no unverified source cited to fill a gap. The grading scheme is set out in our evidence standards, and the main CBG page covers the wider picture.

Common questions

Sources

• Cascio 2010 · PMID 20002104 · In vitro, at the concentration tested, CBG acts as an α₂-adrenoceptor agonist, a 5-HT₁ₐ (serotonin) receptor antagonist and a CB₁ receptor competitive antagonist. Shown in cell assays, a label for the method rather than a grade; the study makes no claim about an effect in a person. It underpins the blood-pressure caution and forms part of the mechanistic background researchers cite for CNS interest, though it offers nothing on neuroprotection.
• De Petrocellis 2011 · PMID 21175579 · In vitro, CBG acts on several TRP ion channels (TRPV1/TRPV2 desensitiser, TRPM8 antagonist). Shown in cell assays, a method rather than a grade. Mechanism only, with no clinical effect shown.
• Borrelli 2013 · PMID 23415610 · CBG reduced inflammation in a mouse model of colitis (gut inflammation). Shown in a mouse model, a method rather than a grade. The result is animal and gut-focused, and it is not evidence of appetite stimulation or neuroprotection in people.
• Appendino 2008 · PMID 18681481 · In vitro, CBG showed antibacterial activity, including against MRSA. Shown in cell assays, a method rather than a grade. Listed for completeness; it has no bearing on neuroprotection, appetite or eye pressure.
• What cannot be cited: none of our verified anchors studies CBG neuroprotection, CBG appetite effects, or CBG and intraocular pressure in humans. Preclinical reports on the first two exist in the wider literature, but they have not been verified into our registry, so those areas are marked catalogue in progress. For glaucoma and eye pressure the record on CBG is No primary evidence. The popular claim is a myth born of confusion with THC and whole cannabis, and an unsupported claim is still different from a disproven one. Binding and potency figures, and dosing, are left out.

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.